GANX – gain therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update [Yahoo! Finance]
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
Gain Therapeutics, Inc. (NASDAQ: GANX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
Form PRE 14A Gain Therapeutics, Inc. For: Jun 24
Form 8-K Gain Therapeutics, Inc. For: Apr 10
Form 10-K Gain Therapeutics, Inc. For: Dec 31
Form 8-K Gain Therapeutics, Inc. For: Mar 27
Form 4 Gain Therapeutics, Inc. For: Mar 20 Filed by: Mack Gene
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.